Table 1 Main characteristics of the included studies
Author | year | country | study design | No.Patients in study | No. PTBD | No. EBD | age(years, median or range) | Male (%) | Maligancy type | Quality assessment* |
|---|---|---|---|---|---|---|---|---|---|---|
Speer AG | 1987 | Enghland | RCT | 75 | 36 | 39 | 50–87 | / | primary carcinoma of the pancreas, gallbladder, or bileducts | 4 |
Piñol V | 2002 | Spain | RCT | 54 | 28 | 26 | 73 | 74 | primary carcinoma of the pancreas, gallbladder, or bileducts,or regional lymph node metastasis | 5 |
Lee SH | 2007 | South Korea | retrospective | 134(34 IPTBD) | 66 | 34 | 67 | 69 | Klatskin’s tumor | 8 |
Saluja SS | 2008 | India | RCT | 54 | 27 | 27 | 51 | 33 | Gallbladder Cancer | 5 |
Paik WH | 2009 | South Korea | retrospective | 85 | 41 | 44 | 66 | 68 | Hilar cholangiocarcinoma | 8 |
Kloek JJ | 2010 | Netherlands | retrospective | 101 | 11 | 90 | 61 | 69 | Hilar cholangiocarcinoma | 7 |
Choi J | 2012 | South Korea | retrospective | 60 | 31 | 29 | 59 | 77 | hepatocellular carcinoma | 7 |
Walter T | 2013 | Canada | retrospective | 129 | 42 | 87 | 66 | 60 | Klatskintumors | 8 |
Huang X | 2015 | China | retrospective | 270(170 no PBD) | 45 | 55(ENBD 18,ERBS 37) | 58 | 71 | extrahepatic bile duct cancer | 7 |
Kim KM | 2015 | South Korea | retrospective | 106 | 62 | 44 | 42–89 | 64 | Perihilar cholangiocarcinomas | 8 |
Inamdar S | 2016 | USA | retrospective | 9135 | 1690 | 7445 | 70 | 50 | pancreatic cancer or cholangiocarcinoma | 6 |
Kishi Y | 2016 | Japan | retrospective | 171 | 98 | 72 | 31–86 | 78 | biliary tract cancer | 7 |
Jo JH | 2017 | South Korea | retrospective | 98 | 43 | 55(13 ENBD, 42 EBS) | 63.5(29–82) | 61 | Klatskin tumor | 8 |
Miura F | 2017 | Japan | retrospective | 88 | 25 | 63 | 70(42–85) | 70 | extrahepatic bile duct cancer | 7 |